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Abstract 
The classification and etiology of functional disorders is controversial. Evidence supports 
both psychological and biological (disease) models that show, respectively, that 
functional disorders should be classified as one (bodily distress syndrome) and many 
(e.g., irritable bowel syndrome (IBS), fibromyalgia syndrome (FMS), and chronic fatigue 
syndrome (CFS)). Two network models (symptom network and adaptive network) can 
explain the specificity and covariation of symptomatology, but only the adaptive network 
model can explain the covariation of the somatic symptoms of functional disorders. The 
adaptive network model is based on the premise that a network of biological mechanisms 
has emergent properties and can exhibit adaptation. The purpose of this study was to test 
the predictions that symptom similarity increases with pathology and that network 
connection strengths vary with pathology, as this would be consistent with the notion that 
functional disorder pathology arises from network adaptation. We conducted a symptom 
internet survey followed by machine learning analysis. Participants were 1751 people 
reporting IBS, FMS or CFS diagnosis who completed a 61-item symptom questionnaire. 
Eleven symptom clusters were identified. Differences in symptom clusters between IBS, 
FMS and CFS groups decreased as overall symptom frequency increased. The strength of 
outgoing connections between clusters varied as a function of symptom frequency and 
single versus multiple diagnoses. The findings suggest that the pathology of functional 
disorders involves an increase in the activity and causal connections between several 
symptom causing mechanisms. The data provide support for the proposal that the body is 
capable of complex adaptation and that functional disorders result when rules that 
normally improve adaptation create maladaptive change.  
 
Keywords : Irritable bowel syndrome; chronic fatigue syndrome; fibromyalgia; 
complexity. 
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Introduction 
Functional disorders, e.g., irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), 
fibromyalgia syndrome (FMS), are a challenge to patients, doctors, society and medical 
science. Patients experience debilitating symptoms and prognosis is poor[1-3]. Treatment 
options are limited and patients sometimes reject the treatment offered[4-5]. Communication 
with patients with CFS and FMS can be difficult[6]. Functional disorders impose economic 
burdens on patients and on health care systems[7]. Although the symptoms of functional 
disorders are classified as medically unexplained symptoms (MUS), two types of explanation 
have been proposed.   
 
The first type of explanation is that functional disorders are a type of mental illness explained 
by psychological theories, and should be referred to as somatoform disorders and treated by 
psychiatrists and psychologists[8-10]. Psychological/psychiatric theories include 
somatization (mental distress becomes bodily distress) and cognitive theories (illness 
cognitions cause maladaptive behavior). These “top down” theories explain the psychological 
antecedents and psychological co-morbidities of functional disorders, and lead to the 
prediction that there is just one type of functional disorder which varies along several 
dimensions[11]. Some evidence supports this prediction. There is considerable overlap and 
similarity between the symptoms of different functional disorders[12], findings that support 
this ‘lumper’ hypothesis. The lumper hypothesis implies that different functional disorders 
should be combined in a single diagnostic category, for example, bodily distress 
syndrome[13,14]. 
 
The second type of explanation is that functional disorders are examples of yet to be 
identified diseases, each disorder being a different disease, i.e., a ‘splitter’ hypothesis. A 
number of biological differences, immune, neurological and endocrine[15-22], have been 
discovered and continue to be discovered between healthy individuals and those with 
functional disorders, but they do not differ consistently between functional disorders. Despite 
this failure, there remains a hope that a specific pathophysiology will be discovered for each 
functional disorder, i.e. different functional disorders have different causes and symptoms. 
 
In summary, some symptom evidence supports the splitter hypothesis as it does the lumper 
hypothesis. The result of a considerable body of evidence is that there is consensus in favor 
of a combination of the lumper and splitter hypotheses and therefore a combination of 
psychological and disease mechanisms [23,24].  
 
There are two network theories that can explain the data that supports both specificity 
(splitter) and commonality (lumper) of functional disorder symptomatology. The first is 
based on the premise that symptoms are part of a causal network, where one symptom can 
cause another. For example, anxiety causes sleep problems, which then causes fatigue that 
then causes depression. The symptom network theory has been used extensively for mental 
disorders[25-28]. The symptom network approach is made plausible by the observation that 
there is some rationale for a causal relationship between one psychological symptom and 
another. That rationale is lacking with functional disorders which include not only 
psychological symptoms but also somatic symptoms. For example, it is difficult to see why 
constipation should lead to diarrhea which is a feature of IBS, or why diarrhea and 
constipation should increase the risk of the fits exhibited by non-epileptic seizure patients[29] 
or the cold periphery of patients with FMS[30]. Thus, although it is possible that some of the 
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commonality of functional disorder symptoms can be explained in terms of a network of 
interconnected symptoms, the symptom network cannot explain why some other symptoms 
are part of that commonality. 
 
The second network theory, the adaptive network theory, is based on the premise that 
symptom clusters are caused by biological mechanisms where different biological 
mechanisms lead to different clusters of symptoms. These biological mechanisms are not 
disease specific in that any one cluster can influence more than one disease – i.e., the 
biological mechanisms lack the specific pathophysiology required for disease classification.  
These biological mechanisms are themselves connected by a network, such that each 
symptom cluster is the result of a putative biological mechanism that then form parts of a 
network [31 - 33]. Although the adaptive network theory shares with the disease concept the 
idea that symptoms are caused by biological mechanisms (including non-specific the 
immune, endocrine, and neurological abnormalities observed in functional disorders), there 
are three differences with standard disease explanations.   
 
The first difference is that whereas there is weak causality between disease mechanisms the 
causality between the symptom-causing functional disorder mechanisms are assumed to 
strongly connected. Weak causality is known to exist between disease mechanisms. For 
example, specific inflammation in chronic obstructive pulmonary disease ‘overspills’ into the 
non-specific inflammatory system, increasing the risk of other diseases that have an 
inflammatory component[34]. Raised levels of non-specific inflammatory mediators are also 
observed in functional disorders so the causal mechanisms between diseases and between 
functional disorders may be the same.  However, in the case of diseases, the inter-disease 
causal connections are relatively weak, so although co-morbidity between diseases occurs, 
each disease can be classified and treated as a discrete pathophysiology. In the case of 
functional disorders, the causal connections are assumed to be strong, so that pathology in 
one mechanism tends to drive pathology in others thereby creating the overlap in 
symptomatology observed with functional disorders. A network of interconnected 
mechanisms will provide a single explanation for both the ‘lumper’ and ‘splitter’ hypotheses 
as well as the lack of specificity of biological abnormalities which is one of the defining 
features of functional disorders. 
 
The second difference with current disease explanations is that psychoneuroimmunological 
mechanisms[35,36] form part of the network of causally connected mechanisms. The 
inclusion of psychoneuroimmunological mechanisms has two consequences. First, it explains 
the psychological antecedents and co-morbidities of functional disorder within a biological 
model.  That is, there is a non-dualist interpretation of psychology theory where 
psychological events are parallel descriptions of the underlying biology, and neither causes 
nor is caused by the other in the strict sense of causal connection. Instead psychological 
events are properties of a biological system, and these properties have no ontological status 
(and therefore have no causal effects) separately from biology. Second, because 
psychoneuroimmunological mechanisms and behaviorally mediated causal pathways are 
known to contribute to disease mechanisms[35,36], psychological factors can be said to 
contribute to the etiology of functional disorders in the same way that that psychological 
factors contribute to disease. 
 
The third difference is that the network of biological mechanisms is assumed to have 
emergent properties that can be understood in terms of system rules, rather than by the 
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underlying biology of the individual mechanisms.  Network structures can exhibit rule 
following behavior, for example, learning rules. Stephen Wolfram [37] has shown that 
programs based on the repetition of simple rules can produce highly complex results, and that 
rule-following cellular automata produce complex outcomes that cannot be predicted 
mathematically from an initial state. As physical science is predicated on mathematical 
prediction, Wolfram argues that the complex patterns that emerge from the repetition of 
simple rules requires “a new kind of science”. The adaptive network theory assumes that 
functional disorders can be explained through the new kind of science proposed by Wolfram, 
namely, where the complexity of functional disorders arises from the repetition of rules, and 
where outcome cannot be determined from the initial biological state. Specifically, the theory 
suggests that the body follows self-organizational rules that are normally adaptive but under 
specific circumstances create illness, these circumstances typically arising when the body 
receives conflicting information on a regular basis. These rules and their outcomes are 
emergent properties of a biological system and therefore need an explanation at that emergent 
level. 
 
The adaptive network theory has been used to explain diseases[38,39] and the functional 
disorders which are the focus of this paper, in particular, chronic fatigue syndrome (CFS) and 
fibromyalgia syndrome (FMS)[40,41]. The theory is supported by evidence that risk factors, 
which include biological and psychological variables associated with these disorders, are 
those predicted by the theory. However, these risk factors can also be explained separately by 
biological and psychological theories, and therefore existing evidence supports not only the 
adaptive network theory but also a combination of biological and psychological theories. The 
present paper does not address the rules themselves, but the more fundamental question of 
whether there is evidence for a network that could exhibit the rules suggested elsewhere. In 
this paper we describe and test two predictions of the adaptive network theory, and explore 
the implications of our findings in terms of how a network might adapt to create the 
pathology of functional disorders. 
 
Predictions of network theory 
The adaptive network theory assumes that symptom causing mechanisms are causally 
connected, and that the pathology in any one mechanism can be represented by the activity 
level of that mechanism as a ‘node’ in a network. Strong interconnectivity causes the activity 
in any one node to spread to other nodes, so as the level of activity in any one node increases, 
it will tend to modulate activation levels in nodes to which it is connected. However, as the 
activation of all nodes increases, the modulatory connections too become more active and 
eventually differentiation between symptom clusters is lost. Without knowing the underlying 
biology, which currently remains obscure, it is possible to model the properties of the 
network only through its outputs (i.e., inferences from symptom clusters rather than biology), 
leading to the prediction that symptomatology across groups of patients should become more 
similar as pathology increases. This prediction is also shared by the symptom network theory, 
but as noted above, the symptom network theory cannot predict the association of 
biologically disparate somatic symptoms. 
 
Networks adapt by alterations in the strength of the causal connections between the different 
nodes in a network. If the nodes of the network are inferred from clusters of symptoms, then 
the empirically derived strengths of causal connections between clusters of symptoms should 
reflect the strength of causal connections between the nodes. We therefore test the prediction 
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that connection strengths between the nodes of a network vary with pathology, as this will 
provide evidence that pathology is associated with network adaptation. 
 
Methods 
Procedure 
Participants were contacted via patient self-help websites for IBS (IBS network), FM 
(Fibromyalgia Association and UK Fibromyalgia) and CFS (Action for ME) and gave online 
informed consent to completing a questionnaire study on their symptoms.  Participants were 
asked to indicate whether they had been given a diagnosis of IBS, FM or CFS ‘by a doctor’ 
(more than one answer was permitted), and they then completed the online questionnaire.  
The 61-symptom frequency questionnaire was based on an existing population 
questionnaire[42], but with modifications to include items specific to IBS, FM and CFS (for 
items see Table 1). The website was open between 10/01/15 and 13/04/16. Institutional 
(University of Plymouth) ethical approval was given. Participants indicated the frequency of 
the symptoms they experienced on a 6 point scale, 0= never or almost never, 1 = less than 3 
or 4 times per year, 2 = every month or so, 3 = every week or so, 4 = more than once per 
week, 5 = every day. We used normalized symptom frequency as data for training a network 
model of symptom relationships. The data set is available from the authors on request. 
 
Machine learning  
To determine the network structure, we adopted a two-step approach, using machine learning 
methods for each that required minimal prior assumptions. In the first step, we clustered 
symptoms to form the nodes of the network, and in the second step, we determined the 
connections between these nodes based on similarities in the activation patterns of the 
symptom clusters. For the first step, we used the K-Means algorithm [44] to determine the 
symptom clusters as this algorithm needs no assumptions about relationships between 
symptoms nor the appropriate size for each of the clusters; i.e., the clustering is determined as 
far as possible by the data (i.e. participants symptomatology). The only completely free 
parameter is the tolerance for determining cluster convergence. The other parameter required 
by K-Means is the number of clusters, which was derived from the data using the silhouette 
method [43]. No explicit regularization was performed at this stage, although to some extent 
an implicit regularization arises from number of clusters used. In the second step, the clusters 
were treated as nodes in a network. Connection strengths between the nodes were calculated 
using the Generalized Hebbian Learning algorithm [45]. To avoid, overfitting of the data, the 
network weights are regularized following an L2-regularisation [68]. The only free parameter 
for this algorithm is the learning rate.  
The resulting trained network, with nodes corresponding to clusters of symptoms, and 
connections between nodes determined by co-activations of nodes, essentially provides a 
descriptor of the symptoms and their relationships irrespective of any particular disorder.  
Although not completely data-driven, our proposed approach requires the choice of only two 
parameters. However, while we found the method to be robust to small variations in these 
parameters, we did not conduct a formal sensitivity analysis of the parameters. (See 
Appendix for full description). 
Statistics 
Testing whether symptom similarity increases with pathology 
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There is no direct measure of pathology.  We therefore used two indicators of pathology as 
proxy: (1) frequency of symptoms, high versus low symptom frequency, (based on a median 
scale score of 0.64, see Table 2 for interpretation), and (2) single versus multiple functional 
disorder diagnosis (one diagnosis of either IBS, FMS or IBS versus two or three diagnoses).  
As we hypothesize that symptom similarity should increase with multiple diagnoses, the test 
of whether symptom similarity increases with pathology is restricted to the single diagnosis 
participants only and a comparison made between those with high versus low symptom 
frequency for each of the three single diagnoses. 
 
The activation level of the symptom clusters was calculated for each of the participants with a 
single diagnosis, where the activation level for each symptom cluster was calculated as the 
mean of the scaled frequencies of the symptoms associated with that cluster for that 
participant. The 3-way interaction (symptom cluster x severity x diagnosis) in an analysis of 
variance with Greenhouse-Geisser correction was used to test whether the degree of 
difference in cluster activation levels differed as a function of high versus low symptom 
frequency. This was followed by one-way analysis of variance (IBS versus FMS versus CFS) 
for each symptom cluster with partial eta squared calculated as effect size to illustrate the 
degree of difference between cluster activation levels for the different diagnoses.  Analysis 
was conducted using SPSS version 23. 
Testing whether connection strengths vary with severity 
Participants were allocated to four groups: low symptom frequency single diagnosis, high 
symptom frequency single diagnosis, low symptom frequency multiple diagnosis and high 
symptom frequency multiple diagnosis. The directed connections strengths between the 
multi-symptom clusters were calculated separately for all four groups. Difference in 
connection strength as a function of severity was tested by treating the total connection 
strengths for each symptom cluster as cases and comparing clusters across groups of 
participants by within-sample t-tests.  
 
 
 
 
Results 
Participants 
Completed questionnaires were received from 1751 participants (1592 female, mean age = 50 
years, age range 16-88 years) of whom 900 participants reported a single diagnosis of either 
IBS, FMS or CFS and the remainder some combination of two or all of these diagnoses. The 
median score used to allocate participants to high or low severity groups was 0.64 (see Table 
2 for interpretation). The numbers in each of the four groups used to compare connection 
strength across groups were: low symptom frequency single diagnosis (n = 617), high 
symptom frequency single diagnosis (n = 283), low symptom frequency multiple diagnosis (n 
= 254) and high symptom frequency multiple diagnosis (n = 595). The 107 participants who 
returned varying degrees of incomplete questionnaires were excluded from the analysis; there 
were an additional 296 hits on the website with no data entered.  
Symptom clusters 
The machine learning procedure produced 11 clusters of symptoms (see Table 1 and Figure 
1), based on covariation of symptoms across the total population of 1751. Of these 11 
clusters, two clusters contained single symptoms. Alpha coefficients for the remaining 9 
clusters with >1 symptom are shown in Table 1. 
Degree of similarity across symptom clusters as a function of level of severity  
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The mean activation levels for single diagnosis high and low severity groups (defined by 
symptom frequency) for each of the 11 symptom clusters is shown in Table 2.  Although 
there is evidence of diagnostic specificity in both high and low severity groups, the degree of 
difference between diagnostic categories is significantly (p < .001) less in the high versus the 
low severity groups. Table 2 shows that the effect size of difference between diagnoses is 
greater for low versus high severity in 7 of the 11 clusters, the reverse is true for 2 clusters, 
and there is no difference for one cluster. 
 Changes in connection strength with severity 
The total absolute incoming and outgoing connection strengths for each of the 9 symptom 
clusters is shown in Figure 2.  There are no significant differences between incoming 
connection strengths. Outgoing connection strengths are significantly lower in the low 
symptom frequency single diagnosis groups when compared with the other three groups (p 
between .005 and < .001). 
 
Discussion 
The symptoms of functional disorders correlate in groups, i.e., symptom clusters, suggestive 
of common causal mechanisms were found. A machine learning procedure identified 11 
clusters of symptoms of which 9 had clinically meaningful groups of symptoms. Symptom 
cluster 6 comprises gastric symptoms plus headaches, indicating involvement of the lower 
gastric tract but with some neurological input. Cluster 5 comprises selected pain symptoms 
plus skin sensitivity and sensitivity to light and noise, consistent with central 
sensitization[15]. Cluster 9 represents symptoms of perceived cold and may involve a 
mechanism of micro-capillary abnormality [30]. The symptoms of cluster 2 appear to be 
associated with hypothalamic-pituitary-adrenal (HPA) axis activation reduced cellular 
immunity associated with long term stress[46].  Cluster 3 comprises a variety of symptoms 
that are known to be associated with the limbic system [47-49]. The symptoms of cluster 4 
are associated with atopic disease. Cluster 8 is a group of mood symptoms, and cluster 11 
symptoms may involve small nerve fiber neuropathy[50-53]. 
Two of the clusters have only one symptom consistent with a specific biological mechanism, 
but other putative mechanisms are not linked to any one disease. There is considerable 
variation in the type mechanism hypothesized for each cluster. For example, the symptoms of 
cluster 4 are all associated with atopic or allergic diseases. The biomarkers of atopy, raised 
levels of IgE, and raised levels of IgE, are found in allergic asthma, eczema and rhinitis. In 
the case of cluster 2, the putative biological mechanism is a causal sequence of several 
biomarkers. Stress leads to autonomic (sympathetic) arousal, which causes raised cortisol 
levels, which have an immunosuppressive effect on cellular immunity, predisposing to a 
range of disease caused by infection as well as other widespread effects of autonomic arousal.  
The biological mechanisms that are inferred from the symptom clusters are therefore highly 
variable, but despite this variability, they make sense both in terms of disease mechanisms 
(e.g., IgE) and the non-specific autonomic, endocrine and immune abnormalities that have 
been observed in functional disorders [15-22]. 
This study tested two novel predictions from network theory. First, there was evidence that 
symptom similarity increased with symptom frequency. This finding shows that, whatever 
the underlying mechanisms, the mechanisms causing the different symptoms are not 
independent but are causally connected to each other. This finding is inconsistent with a 
combination of biological and somatization explanations. The biological and somatization 
explanations both predict that symptom similarity should be independent of severity. The 
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finding is consistent with both symptom network and adaptive network theories. Although 
the symptom network theory has considerable support in the case of mental disorders [25-28], 
it has difficulty explaining the covariation of some somatic symptoms, including the 
covariations found here in some of the symptom clusters (e.g., diarrhea and constipation).  
The second finding was that outgoing connection strengths were lower for participants who 
had the lowest indicators of pathology (i.e., single diagnosis and low symptoms frequency).  
This finding suggests that the structure of the network changes with pathology. Taking the 
first and second findings together, the results suggest that increased pathology involves (a) 
greater activity in the nodes of the network and (b) increased connection strength between the 
nodes. We do not know why change in connection strength is limited to outgoing 
connections, but it would appear that as pathology increases, so each of the different 
mechanisms becomes more sensitized to the activity of its neighbors. Given that sensory 
sensitization is a feature of functional disorders, it is interesting that the pathology of 
functional disorders also appears to involve sensitization between biological mechanisms. 
Limitations 
The method for identifying symptom clusters is known to be methodology dependent.  For 
example, several studies have used exploratory factor analysis to identify functional disorder 
symptom clusters. These studies produce different numbers and groupings of symptoms [54-
58]. There are two possible interpretations for the variation in findings. One is that it a 
methodological problem that is solved only by finding the ‘correct’ methodology. The other, 
the one we prefer, is that the underlying biological network structure makes it possible to 
have different, equally valid, groupings of symptoms.  For example, cluster 4 (atopy) is 
linked to just one biomarker, and the atopic symptom cluster is retained if our data are 
subjected to factor analysis (principal axis, 11 factors, varimax rotation). However, with the 
same factor analysis, the symptoms of cluster 2 are separated into different factors 
representing autonomic and immune related symptoms. That is, the combined autonomic-
immune causal sequence identified in the machine learning analysis is not found in the factor 
analysis.  Similarly, the pain symptoms and sensitivity to light and noise of cluster 5 are both 
linked to central sensitivity, but these two types of symptoms form separate clusters in the 
factor analysis, consistent with central sensitivity differing between modalities.   Variability 
of interpretation follows if, in a network of mechanisms, it is possible to group those 
symptoms and therefore mechanisms in different ways. Some symptom clusters will be the 
result of just one mechanism and these will tend to be consistent across methodologies. 
However, where symptom clusters depend on interconnected mechanisms, then different 
methodologies will reveal different types of interconnection. Our results show that it is 
possible to provide a useful description of our data in terms of 11 clusters of symptoms – not 
that there really are 11 and only 11 clusters. 
The number of clusters will have comparatively little bearing on tests of difference between 
the high and low severity participants. However, correlations obtained from subpopulations 
are known to differ from correlations of the total population. The comparison of different 
subpopulations raises the possibility of bias in any statistical analysis of symptom 
association. We have been unable to determine the direction of any bias, but the possibility of 
bias need to be acknowledged. 
The data presented here are consistent with the hypothesis that the symptoms of functional 
disorders are caused by a network of interacting biological mechanisms. However, the data 
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are also consistent with the hypothesis that symptoms cause symptoms. The network of 
symptom clusters found in this study could be made up of clusters from two sources:  
symptom-symptom clusters and biological mechanism-symptom clusters. Additionally, any 
of the putative functional disorder mechanisms may be causally connected to disease 
mechanisms. A study where there is a combination of symptom analysis with biomarkers will 
provide a better understanding of the underlying biological mechanisms than the present 
study which is limited only to symptoms. Nevertheless, this study does provide useful 
pointers towards biological markers of likely interest. 
From networks to rule following adaptation 
Our research was motivated by the hypothesis that functional disorders are the consequence 
of network adaptation. It is known that the body can adapt – examples include simple 
adaptation to repeated stress (biomarkers of stress increase with repeated stress) and drug 
tolerance effects (drugs become less effective over time) – but a network provides the 
possibility of more complex forms of adaptation, in particular where there are conflicting 
inputs[41]. One proposal is that if a person persists in activities that create fatigue or pain, 
then the symptoms of fatigue and pain potentiate, doing so because the system is designed to 
optimize control feedback loops[32,33,40,41]. The hypothesis that symptoms potentiate when 
they fail to alter behavior has also been proposed separately in relation to affective 
disorders[59-61, and this compensation rule [41] is consistent with other forms of data[62-
64]. Whereas the present study provides no information about whether these algorithms are 
correct, it does provide evidence of a network capable of complex rule following, and 
suggests that rules may differ between mild and more severe patients with functional 
disorders. Thus, it contributes towards a new understanding of the cause and treatment of 
functional disorders. 
In summary, the data are consistent with both the symptom network and adaptive network 
theories and show that the covariation of symptoms of functional disorders cannot be 
explained through a single common cause of somatization – though somatization may still be 
occurring. The symptom network theory cannot explain the covariation of all the symptoms 
assessed in this study and requires the addition of a biological explanation for at least one 
symptom. However, the symptom network theory is not incompatible with the adaptive 
network theory as symptom networks are likely to reflect both types of causality.  Our finding 
make plausible the proposal that the body is a biological network that follows rules of 
adaptation. The hypothesis that the body exhibits complex adaptation provides a new way of 
conceptualizing functional disorders, one that emphasizes the role of lifestyle. Although the 
importance of lifestyle is emphasized in current guidelines[65,66], this study might provide a 
further impetus for exploring the importance of temporal patterning in the development of 
pathology and recovery, and might provide a useful guide for therapeutic practice[67].    
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Table 1. Symptom clusters and reliability of each cluster group 
Cluster number 
and reliabilitya 
Symptoms 
1 
.89 
 
Fatigue for no reason; Fatigue increasing the day after you are active; Waking up still feeling 
tired; Mental fog; Difficulty concentrating; Memory problems; Easily feel too hot/sweating; 
Difficulty getting to sleep; Waking up often at night 
2 
.81 
 
Nightmares/night terrors; Head cold, sore throat or 'flu; Mouth ulcers (sores in mouth); Cold sores 
(on or near lips); Skin rash; Boils or pimples on face or body; Twitching of eyelid; Twitching 
other than eyelid; Choking sensations; Loss of voice; Double vision 
3 
.78 
 
Chest pain; Heartburn; Nausea for no reason; Very vivid dreams; Racing heart; Feeling faint; 
Feeling very ill for no reason 
4 
.76 
 
Thirsty all the time; Blocked nose; Running nose; Itchy skin; Itchy eyes 
5 
.90 
 
Pain in legs and arms (which is not due to hard exercise); Pain moving from one place of body to 
another on different days; Back pain; Sensitive or tender skin; Pain increasing the day after you 
are active; More clumsy than others; Sensitivity to bright lights; Sensitivity to noise 
6 
.67 
 
Headaches; Stomach pain; Diarrhoea; Constipation; Bloating of the stomach; Intolerant to some 
food 
7 
- 
 
Urinating two or more times per night 
8 
.88 
 
Depression; Feeling anxious for no reason; Irritable; Jittery. Easily startled, often worried 
9 
.85 
 
Easily feel too cold; Very cold hands or feet 
10 
- 
 
Ringing in ears 
11 
.81 
 
Swollen, painful joints; Fatigue increasing after a cold or sore throat; Hands tremble or shake; 
Face flushes; Cramps in leg, foot or bottom; Numbness/tingling/pins and needles; Feeling out of 
breath for no reason 
a alpha coefficient 
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Table 2.  Mean (standard deviations) of activation levelsa of groups of participantsb when 
presented to the clusters and cluster characteristics. 
Cluster no. 
Reliabilityc 
(n items) 
IBS-low, N 
= 321 
FMS-low, 
N = 198 
CFS-low, 
N = 98 
Effect  
sized 
 low 
IBS-high, 
N = 49 
FMS-high, 
N = 186 
CFS-high, 
N = 48 
Effect sized 
 high 
1 
.89 
(9) 
0.57 (0.09) 0.80 (0.07) 0.82 (0.06) .371*** 0.89 (0.04) 0.93 (0.03) 0.92 (0.03) .057*** 
2 
.81 
(11) 
0.27 (0.03) 0.29 (0.04) 0.32 (0.04) .049*** 0.44 (0.05) 0.46 (0.06) 0.48 (0.05) .009 
3 
.78 
(7) 
 
0.41 (0.07) 0.42 (0.06) 0.51 (0.07) .076*** 0.72 (0.06) 0.67 (0.06) 0.70 (0.06) .021 
4 
.76 
(5) 
0.46 (0.08) 0.52 (0.09) 0.44 (0.08) .034*** 0.73 (0.08) 0.74 (0.07) 0.71 (0.08) .006 
5 
.90 
(8) 
0.41 (0.07) 0.73 (0.07) 0.63 (0.09) .489*** 0.78 (0.06) 0.91 (0.04) 0.84 (0.05) .242*** 
6 
.67 
(6) 
0.65 (0.06) 0.48 (0.07) 0.49 (0.07) .294*** 0.80 (0.05) 0.69 (0.06) 0.68 (0.06) .123*** 
7 
- 
(1) 
0.43 (0.15) 0.45 (0.16) 0.43 (0.15) .001 0.64 (0.15) 0.68 (0.16) 0.63 (0.16) .005 
8 
.88 
(4) 
0.54 (0.12) 0.56 (0.10) 0.50 (0.11) .007 0.86 (0.07) 0.81 (0.08) 0.75 (0.10) .046** 
9 
.85 
(2) 
0.61 (0.15) 0.74 (0.14) 0.69 (0.14) .038*** 0.91 (0.09) 0.88 (0.09) 0.91 (0.07) .004 
10 
- 
(1) 
0.41 (0.15) 0.47 (0.16) 0.48 (0.15) .010* 0.57 (0.16) 0.65 (0.16) 0.65 (0.15) .010 
11 
.81 
(7) 
0.37 (0.07) 0.52 (0.07) 0.49 (0.06) .208*** 0.65 (0.07) 0.77 (0.05) 0.71 (0.05) .128*** 
a Interpretation of symptom frequency from activation levels: 0.16 = never or almost never, 
0.33 = less than 3 or 4 times per year, 0.5 = every month or so, 0.66 = every week or so, 0.83 
= more than once per week, 1.0 = every day. 
b Activation levels calculated for those 900 participants who report only one diagnosis. 
c Reliability (alpha coefficients) calculated from the total 1751 sample. 
d Effect size (partial eta squared) calculated from one-way analysis of variance comparing 
IBS, FMS and CFS groups and where *p<.05, **p<.01, ***p<.001.  
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Figure 1.  Figure 1 shows the network created by our algorithm. Each node in the graph, 
corresponds to a cluster with the size of the nodes scaling according to the number of 
symptoms contained in each cluster. The edges connecting the nodes represent the 
connections between the clusters. Their size varies with respect to the strength of each 
connection, showing the value difference between in-coming and out-going connection for 
each edge. 
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Figure 2. Incoming and outgoing connection strengths of nine clusters as a function of 
severity. 
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Appendix  
Finding the symptom clusters 
Each symptom was treated as a point, p, in an m-dimensional space, where m is the number 
of participants in the dataset. The distance,  𝑑(𝑝𝑎, 𝑝𝑏) between two points, 𝑝𝑎, 𝑝𝑏 was defined 
as: 
𝑑(𝑝𝑎, 𝑝𝑏) = √∑ (
𝑚
𝑖=1 𝑝𝑎𝑖 − 𝑝𝑏𝑖)
2    [1] 
Symptoms were clustered based on the frequency of their co-occurrence across participants. 
This approach resulted in a set of network nodes, each characterized as a cluster of 
symptoms. To find the symptom clusters, the K-Means[44] algorithm was used. This is a 
well-known method that has been widely used across a range of fields [31]. The principle 
underlying the algorithm is to cluster the data into n groups by minimizing the within-cluster 
sum-of-squares.  
The algorithm consists of the following steps: 
1. Start with initial guesses for cluster centres; random points in the feature space. 
2. For each symptom vector, find the closest cluster centre (partitioning step). 
3. Replace the centroid of each cluster by the average of the symptom vectors in its 
partition 
4. Iterate 1+2 until convergence 
 
The only free parameter is the tolerance for determining cluster convergence (= 0.0001). 
The other parameter required by K-Means is the number of clusters, n. The best choice for n 
was determined from the data using the silhouette method [43]. The result of this stage of 
processing was a set of 𝑛 = 11 symptom clusters, each of which had similar variance across 
the set of patients.  
Determining the network’s connectivity 
Having clustered the symptoms to form the nodes of the network, the next step was to form 
the connections between the nodes. Each node has the potential to connect to every other 
node. The strengths of the connections between them regulate the activation propagated 
between the connected nodes when the completed network is activated with the participant 
data. 
At this stage, instead of considering each symptom as a point in the data space, each patient 
was treated as a 61-dimensional point, q, with 61 features corresponding to their scaled 
questionnaire responses. To determine the network connectivity, the data relating to each 
participant was used as input to the network. In what follows the term ‘presenting a 
participant to the network’ refers to the procedure of activating the network with a particular 
participant 's data. Participants were presented to the network in random order.  
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Following presentation of each item, the connection strengths between all pairs of nodes i and 
j (where i, j = 1:n, i ≠ j) was calculated according to the Generalized Hebbian Algorithm 
[33]: 
∆𝑤𝑖𝑗 =  𝜀(𝑦𝑖𝑥𝑗 −  𝑦𝑖 ∑ 𝑤𝑘𝑗
𝑛
𝑘=1,𝑘≠𝑗 𝑦𝑘)  [2] 
 
where 𝑤𝑖𝑗 is the connection strength from node i to j, and 𝜖 is the learning rate; 𝜖, the only 
free parameter in this stage was set to 0.01. The input vector, 𝑥, is the initial activation of the 
nodes derived from the participant's data. The output vector, 𝑦, represents the activation of 
the nodes based on the propagation of the initial activation throughout the network. 
In detail, presentation of each participant to the network proceeds as follows. First the initial 
activations of the nodes are determined by the participant's scaled symptom scores. Each 
node is activated by sum of its associated symptom scores from that participant; i.e. for node 
𝑖: 
 𝑥𝑖 = tanh [
1
𝑁𝑖
∑ 𝑞𝑘  
𝑁𝑖
𝑘=1 ]  [3] 
where 𝑁𝑖  is the number of symptoms in cluster 𝑖 and 𝑞𝑘 is the scaled magnitude of each 
symptom. The hyperbolic tangent function, tanh, constrains the initial activation values to lie 
in the range [0,1]  and ensures that each cluster contributes equally to the initialization of the 
network regardless of the number of symptoms associated with it. After presentation of all 
participants, the connection strengths are normalized: 
𝑤𝑖𝑗 =
𝑤𝑖𝑗
√∑ 𝑤𝑘𝑙
2𝑛
𝑘,𝑙=1,𝑘≠𝑙
   [4] 
The resulting trained network, with nodes corresponding to clusters of symptoms, and 
connections between nodes determined by co-occurrences of symptoms, essentially provides 
a descriptor of the symptoms and their relationships, irrespective of any particular disorder.  
 
 
